Company confirms Hugo RAS system submission to the U.S. Food and Drug Administration ...

Written by: Eman N. Chaudhri, MD, Department of Urology, University of California, Irvine, @EmanChaudhri on Twitter during the American Urological Association's 2025 Annual Meeting, between April 26 – ...

Dr. Huang concluded this presentation discussing results of a phase II study of tislelizumab as neoadjuvant treatment for cisplatin-ineligible high-risk upper tract urothelial carcinoma with the ...

(UroToday.com) The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025 in Las Vegas, Nevada, was host to the Society of Urologic Oncology (SUO) Session. Dr. Bernard ...

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

Of the 422 patients, 198 (47%) experienced a recurrence following surgery. There was an almost even split between early (34%), mid (33%), and late recurrences (32%). Time to recurrence was associated ...

Each patient underwent sequential laser activation in three commonly used modes: fragmentation (low power), dusting (moderate power), and pop-dusting (high power), with temperatures recorded ...

Dr. Kazuyuki Numakura presented a study of primary resistance to nivolumab + ipilimumab therapy affecting second-line treatment outcomes in metastatic renal cell carcinoma (mRCC) patients. Long-term ...

Data was drawn from the Urology Residency Match (SAU Match) survey administered annually by the AUA. Participation remained strong across the three years, with 440, 428, and 387 applicants responding ...

(UroToday.com) The American Urological Association (AUA) 2025 Annual Meeting, held in Las Vegas, NV, was host to an advanced prostate cancer podium session. Dr. Alejandro Sanchez presented the results ...

The SOPHIA study retrospectively investigated the first-in-man safety and efficacy in 6 patients with stress urinary incontinence who received the UroActive TM device. Results from the primary ...

Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in ...